![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 30, 2006 7:15:51 PM
INSM Investors
by: supacharja 01/30/06 06:59 pm
Msg: 60736 of 60751
I forgot why I stopped visiting this board until I began perusing some of the posts. From posters supposedly sending emails to INSM's IR dept to traders looking at "technical indicators," this board has become unintelligible.
I've been long this Company for a long time. And I have no near to intermediate term plans to relinquish any portion of my INSM holdings.
I have some thoughts for those investors concerned about their INSM investment. First, technical analysis is a waste of time with this Company, as there are esoteric forces currently at work which have been and will affect the share price. Second, the transition from a research to a commercial operation takes time. Essentially INSM was born on Dec. 12, less than 2 months ago. Third, the IR dept won't pander to the small investors sense of anxiety. In fact, doing so would be a disservice to the other investors that presumably hold the other 99.9999% of the shares outstanding (fully diluted that stands at 98 million).
The bottom line is that management is busy building this company. Could they have done some things differently in the past....arguably yes. But realize that this management has succeeded in developing a science that is revolutionary, and which will finally be delivered to the marketplace after many, many years. Ultimately there will be many other uses for iPlex outside of IGFD. Remember that management is not concerned with the short-term movement in the stock price. No management should be...they have a fiduciary responsible to build long-term value. It's taken a long time to get to where we are today....giving the stock a little time to appreciate seems reasonable. For those that invested at higher levels and can give this Company some time, relax. INSM the Company, and stock, will be fine.
Recent INSM News
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 12:00:00 PM
- Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference • PR Newswire (US) • 07/03/2024 01:03:00 PM
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 • PR Newswire (US) • 06/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:21:15 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:23:25 PM
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:00:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:44:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:41:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 09:32:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 08:15:33 PM
- Insmed to Host Commercial Webinar on June 4, 2024 • PR Newswire (US) • 05/30/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/30/2024 08:02:27 PM
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Insmed Announces Proposed $500 Million Public Offering of Common Stock • PR Newswire (US) • 05/28/2024 10:21:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:51:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:49:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:47:36 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:46:34 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM